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EMERGING TECHNOLOGIES 
Implantable Devices 
in ihe Coronary Artery 
From Metal to Genes 
David W.M. Muller and Eric J. Top01 
Preliminary data from nonrandomized clinical trials suggest that, in 
selected subgroups of patients, the implantation of endovascular stents 
may improve the initial results of coronary dilatation, may successfully 
treat arterial dissection and abrupt closure, and may reduce the 
incidence of recurrent stenosis. The widespread use of stents remains 
limited, however, by the need for intensive anticoagulation to prevent 
arterial thrombosis. The development of sustained-release drug delivery 
systems and gene-transfer technology may enable local delivery of 
antithrombotic and antiproliferative therapies that would greatly 
increase the safety and applicability of these devices. (Trends Cardio- 
vast Med 1991; 1:225-232) 
Over the past decade, the options availa- 
ble for the management of symptomatic 
coronary artery disease have increased 
considerably. In addition to surgical 
revascularization, several percutaneous 
procedures, inciuding baiioon an- 
gioplasty, laser ablation, atherectomy, 
and endovascular stenting, have been 
evaluated clinically and have proved to 
be effective in relieving obstructive coro- 
nary stenoses (Karsch et al. 1990; Safian 
et al. 1990; Schatz et al. 1991). The 
long-term efficacy of each of these proce- 
dures remains iimited. however. bv re- 
current stenosis due to neointimal thick- 
ening, a process that appears to be 
resistant to a variety of systemic phar- 
macologic therapies (Liu et al. 1989; 
Califf et al. 1990). As more detailed 
information has become available about 
the .histopathology of restenosis follow- 
ing these interventions, and the cellular 
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and molecular mechanisms that contrib- 
ute to its development, the attention of 
many investigators has turned to the 
possibility of combining mechanical in- 
terventions, such as endovascular stent- 
I__ -..lrL 1-_-l ~~1~~~~~~~~~1~~~~ A,_____ mg, wlm local pnarmacologic rnerapy to 
control the events that follow arterial 
injury. This review summarizes the pros- 
pects for the therapeutic control of coro- 
nary arterial disease with implantable 
intravascular devices and with proce- 
dures that provide chronic, sustained 
release of local drug therapies. 
l Rationale for 
Endovascular Therapy 
Percutaneous coronary balloon angio- 
plasty, the most frequently performed 
coronary interventional procedure, can 
be accomplished with a high acute suc- 
cess rate (Detre et al. 1989). The proce- 
dure remains limited, however, by the 
risk of medial dissection and abrupt 
coronary occlusion, and by recurrent 
stenosis at the site of bailoon dilatation. 
The incidence of abrupt closure follow- 
ing balloon angioplasty is -6%-7% (Detre 
et al. 1989) and restenosis occurs within 
6 months of angioplasty in X5%-45% of 
natif=nts ttYC3t6Tl (Califf F?i a!. l??Q); Pest- r ____ **_I -- ----_ \ _----- 
mortem histologic studies of patients 
dying several months after balloon an- 
gioplasty have shown that the predomi- 
nant cause of restenosis is extensive 
neointimal thickening due to smooth 
muscle cell proliferation at sites of dis- 
ruption of atheromatous plaque and the 
underlying media (Austin et al. 1985; 
Essed et al. 1983). The factors that 
influence this proliferative response re- 
main poorly understood. It is likely that 
any injury that exposes subintimal com- 
ponents of the vessel wall will stimulate 
the adhesion and activation of platelets, 
Lx-al thrnmhl,r fnrmatinn am-l the r~_ AV1..A ...A_--.l_” AY-..a-.^Y”, ._._._ . .._ Iu 
lease of growth factors. Mitogenic fac- 
tors, derived from platelets, macrophages, 
and the endothelium, promote medial 
smooth muscle cell proliferation and 
migration, and the synthesis and secre- 
tion of connective tissue matrix (Liu 
1989). Preliminary data suggest that this 
process occurs to a similar degree and 
with a similar time course following 
balloon angioplasty, coronary atherec- 
tomy, laser ablation, and endovascular 
stenting (Waller et al. 1990). 
These observations suggest that no 
mechanical device will eliminate the 
_.~~_l.P ..___ prourerauve response to injury. In the- 
ory, however, endovascular stenting of- 
fers several advantages over other meth- 
ods of percutaneous revascularization. 
First, the stents provide an intravascular 
scaffold to oppose the vasoconstriction 
and recoil that commonly follow balloon 
angioplasty (Fischell et al. 1988) and 
that may be responsible for the recur- 
rence of some stenoses (Waller 1985). 
Second, intravascular stents may mini- 
mize the extent to which subintimal 
tissues are exposed to the circulation by 
compressing dissected layers of the arte- 
rial wall, thereby reducing the stimulus 
to intimal proliferation. Third, by opti- 
mizing the caliber of the diseased arte- 
rial segment after dilatation, stenting 
may minimize the physiologic signifi- 
cance of any intimal thickening that 
does subsequently occur (Ellis et al. 
1990a). Finally, although not yet re- 
ported in in vivo models, the implanta- 
tion of polymeric stents or poiyr?lpr- 
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Figure 1. The articulated PaImaz-Schatz coronary stent before and after balloon inflation. 
From Muller et al. (1990a). 
coated metallic stems may enable the 
delivery of high-concentration, local phar- 
macologic agents at the site of vascular 
injury. To date, the potential of this 
combined mechanical and pharmacol- 
ogic approach to optimize both the 
short- and long-term efficacy of percuta- 
neous coronary revascularization remains 
speculative, as several technical consider- 
ations. outlined below; have slowed the _.______, __..~~~~_ _ ___ 
development of such devices. On the 
other hand, considerable clinical and 
experimental experience has been accu- 
mulated with the implantation of un- 
coated metallic stems; considerably less 
experience has been accumulated with 
stents made from synthetic polymers. 
l Metallic Stents 
The implantation of metallic stems was 
originally conceived as a means of main- 
taining arterial patency following dilata- 
tion of obstructive stenoses more than 20 
jr-= 
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advantage of metal over other materials 
is its high long-term structural integrity 
combined with a relatively low profile 
and small surface area. The principal 
disadvantages of these materials, on the 
other hand, include their relative inflexi- 
bility, their propensity for thrombosis, 
and the susceptibility of some metals to 
corrosion. Other considerations in the 
selection of the stent material include its 
radiopacity and long-term biocompati- 
bility. To date, the most commonly 
employed metal has been stainless steel, 
which is biologically relatively inert. Its 
use as an endovascular prosthesis has 
been limited, however, by its poor radio- 
pacity and predilection for thrombosis. 
Tantalum, which is considerably more 
radiopaque than stainless steel, also has 
elastic properties that make it suitable 
for balloon delivery, but, like stainless 
steel, tantalum is also thrombogenic 
(Bertrand et al. 1990). The metallic 
stems vary not only in the materials 
employed, but also in the mechanism of 
deployment. These mechanisms include 
balloon expansion, self-expansion, and 
activation by temperature-dependent 
changes in metal configuration (thermal 
memory stents j . 
Balloon-Expandable Stents 
At least six balloon-expandable stems 
are currently under clinical or preclini- 
cal evaluation for implantation in coro- 
nary arteries. The Palmaz-Schatz stainless- 
steel stent (Johnson and Johnson Inter- 
ventional Systems, Warren, NJ, USA) 
has a slotted, tubular configuration prior 
to deployment. During balloon expan- 
sion, it takes on a rigid, diamond-mesh 
appearance (Figure 1). The stent is 15 
mm long and has a l-mm articulation at 
its center to enable greater flexibility 
during positioning and deployment. A 5 
French outer sheath is used to protect 
the stent and to prevent its dislodgment 
from the balloon catheter during im- 
plantation. Prior to balloon inflation, the 
sheath is withdrawn to enable unre- 
stricted balloon and stent expansion at 
Figure 2. The Gianturco-Roubin coronary stent before and after balloon inflation. From 
MulIer and Ellis ( 1990b). 
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the site of the coronary stenosis. The 
Gianturc+Roubin stent (Cook Inc., Bloom- 
ington, IN, USA) is 20 mm long and has 
an interdigitating coil configuration (Fig- 
ure 2). Two versions of the stent, one 
stainless steel and one tantalum, are 
being evaluated in clinical and experi- 
mental studies. The Medtronic Wiktor 
stent (Medtronic Inc., Minneapolis, MN, 
USA) is made of tantalum and has a 
flexible, open-weave configuration. It is 
20 mm long and has a wire thickness of 
0.125 mm (Figure 3). The Cordis Coro- 
nary Stent and Delivery System (Cordis 
Corporation, Miami, FL, USA), like the 
Medtronic Wiktor stent, is a coiled, 
tantalum device 16-22 mm long, with a 
wire thickness of 0.125 mm. The Boneau 
ZZ is a stainless-steel stent under early 
experimental evaluation (Anwar et al. 
1990), and the Strecker stent (Medi-Tech, 
Watertown, MA, USA) is a tantalum, 
interwoven wire-mesh stent that has 
been used in European clinical trials for 
the treatment of peripheral vascular 
stenoses (Becker 199 1). 
Self-Expanding Stents 
The Wallstent (Medinvent SA, Lausanne, 
Switzerland) is stainless steel and varies 
in length from 15 to 30 mm. The woven 
mesh device is delivered on a catheter, 
on which it is compressed by a doubled- 
over retaining membrane (Figure 4). 
Gradual withdrawal of the membrane 
allows the stent to expand to a predeter- 
mined size and to the shape of the 
Figure 3. The Medtronic Wiktor coronary stent 
stented vessel. Polymer-coated versions 
of the stent have recently been implanted 
in experimental animal models. 
Thermal Memory Stents 
Some metal alloys, such as nickel- 
titanium (nitinol), undergo a striking 
conformational change when exposed to 
changes in temperature. These metals 
can be annealed to a desired configura- 
tion, diameter, and length at high tem- 
peratures. At room temperature, the 
device can be shaped to a second, low- 
profile, flexible configuration that allows 
it to be readily delivered to the site of the 
coronary stenosis. Subsequentrewarming 
by heated normal saline causes the metal 
to resume its original crystalline struc- 
ture and configuration. The feasibility of 
deploying such devices has been demon- 
strated in experimental studies (Sutton 
et al. 1990), but clinical studies have not 
yet been performed. 
l Indications for Metallic Stent 
Implantation 
The development of intravascular stent- 
ing as an alternative to coronary balloon 
angioplasty was based on three potential 
clinical indications for this approach: (a) 
to optimize the initial angiographic re- 
sults of the intervention, (b) to prevent 
restenosis, and (c) to manage severe 
medial dissection and abrupt arterial 
closure following coronary balloon an- 
gioplasty. 
Figure 4. The self-expanding Wallstent be- 
fore, during, and after removal of the retain- 
ing membrane. From Muller and Ellis (199Ob). 
Initial Angiographic Results 
With careful patient selection, acute suc- 
cess rates for metallic stent implantation 
have been high (90%95%) and, in most 
series, immediate angiography has shown 
excellent results with a mean residual 
stenosis severity of ~20% by quantitative 
coronary angiography (Schatz et al. 199 1; 
Levine et al. 1990). Although randomized 
comparisons between coronary stenting 
and balloon angioplasty have not yet 
been performed, one case control study 
suggested that the residual luminal diam- 
eter may be greater following stent 
implantation than following balloon an- 
gioplasty (Muller et al. 1990a). 
Prevention of Restenosis 
Early, nonrandomized data from several 
centers suggest that, in selected patient 
populations, the incidence of restenosis 
may be lower following intravascular 
stenting than following balloon angio- 
plasty. In one series of 83 patients 
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Figure 5. Histologic section 3 months following implantation of a coronary Wallstent showing 
intimal proliferation overlying and between the sttuts of the stent. Courtesy of the Schneider US 
Stent Division (Plymouth, MN, USA). From Muller and Ellis (1990b). 
(Fajadet et al. 1990), the incidence of 
angiographic restenosis (defined as a 
stenosis 250% luminal diameter) 6 
months after coronary stenting (Palmaz- 
Schatz device) was 16.9%. A 17% inci- 
dence of restenosis was also noted in a 
series of 18 patients with single right 
coronary artery stents (Levine et al. 
1990). However, the incidence of resten- 
osis appears to be highly dependent on 
the size of the stented vessel and on the 
length of the lesion. In particular, the use 
of multiple, overlapping stents (Ellis et 
al. 1990b; Levine et al. 1990) or stent 
implantation in arteries of <3.2 mm in 
diameter (Ellis et al. 199Ob) have been 
associated with restenosis rates of ~50%. 
The apparent reduction in the inci- 
dence of restenosis in large arteries with 
discrete stenoses has been attributed to a 
greater initial increase in coronary lumi- 
nal diameter, rather than to a reduction 
in the severity of the intimal proliferative 
response (Ellis et al. 1990a). Some degree 
of neointimal thickening appears to be 
invariable. Experimental studies have 
shown that, following stent implantation, 
the metallic struts of the device rapidly 
become covered with a fine layer of 
confluent endothelial cells (Schatz et al. 
1987). Thereafter, the intimal thickness 
overlying and between the stent struts 
increases progressively, to peak -2-3 
months after stent implantation (Figure 
5). At 6 months, the intimal thickness 
overlying the stent typically ranges from 
100 to 450 pm (Roubin et al. 1987; 
Sigwart et al. 1987). Thus, the implanta- 
tion of metallic stents does not prevent 
the reparative response of the vessel wall 
to injury, but instead may reduce its 
physiologic significance by maximizing 
the initial coronary luminal diameter. 
Management of Abrupt Closure 
Although relatively uncommon, abrupt 
closure following balloon angioplasty is 
associated with a high morbidity and a 
relatively high mortality (Detre et al. 
1989). The availability of endovascular 
stents to seal arterial dissections and to 
restore rapidly coronary flow greatly 
increases the overall safety of percutane- 
ous coronary interventions and the con- 
fidence with which high-risk interven- 
tions can be undertaken. Each of the 
clinically available metallic stents has 
been used successfully for the manage- 
ment of abrupt closure or of threatened 
closure associated with a suboptimal 
postangioplasty angiographic appearance 
(Sigwart et al. 1987; Roubin et al. 1990a; 
Schatz et al. 1990). Intravascular stems 
were initially used in this setting as a 
bridge to emergency coronary artery 
bypass graft surgery, but more recently 
coronary stenting has been used to obvi- 
ate the need for urgent surgery (Figure 
6). Whether this approach is associated 
with a satisfactory long-term outcome 
remains to be determined. In one series 
of 32 patients with long-term angiogra- 
phic follow-up, for example, the inci- 
dence of restenosis within 6 months of 
stent implantation for actual or threat- 
ened abrupt closure was 44% (Roubin et 
al. 1990b). These findings require confir- 
mation in larger studies and may actually 
Figure 6. Successful management of abrupt right coronary closure by insertion of three 
Gianturco-Roubin stents. From Muller and Ellis (1990b). 
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be no worse than following successful creases the potential for bleeding com- 
balloon angioplasty associated with tran- plications, and periaccess site, retroperi- 
sient abrupt vessel closure (Ba’albaki et toneal, and gastrointestinal bleeding has 
al. 1990). An alternative to permanent occurred relatively commonly in most 
intravascular stenting for abrupt closure centers during early experience with stent 
may be the use of temporary, retrievable implantation. Furthermore, the need for 
devices. Experience with one such device a prolonged hospital stay and careful 
(Didier et al. 1991) suggests that tempo- monitoring of the patients’ anticoagulant 
rary, prolonged compression may be ade- therapy may also increase the cost of the 
quate to seal a dissection flap successfully procedure (Dick et al. 1990). Whether this 
and to avoid the morbidity associated apparently greater cost is justifiable on 
with permanent stenting or urgent coro- the basis of improved long-term results 
nary artery bypass graft surgery. remains to be evaluated. 
l Major Limitations of Metallic Stents 
In their current designs, metallic stems 
are limited principally by their inflexibil- 
ity and by the need for several months of 
intensive anticoagulation therapy to pre- 
vent early thrombotic closure. The low 
flexibility of the devices precludes their 
use in tortuous, heavily calcified vessels 
and demands the use of large-caliber 
guiding catheters to provide adequate 
support during deployment. This not 
only increases the potential for guide- 
catheter-induced ostial dissections, but 
also increases the likelihood of femoral 
access site hemorrhagic complications. 
Subacute stent thrombosis remains a 
significant hazard. In the absence of an 
intensive anticoagulation regimen, throm- 
botic closure of the stented vessel occurs 
frequently during the first 2-3 weeks. In 
a series of 2 13 patients in whom Palmaz- 
Schatz stents were implanted electively, 
the incidence of subacute closure was 
18% in 39 patients who received 
periprocedural heparin, aspirin, dextran, 
and dipyridamole compared with 0.6% 
in the remaining patients, all of whom 
were fully anticoagulated for 3 months 
(Schatz et al. 1991). A similarly high 
early thrombosis rate (25% in patients 
inadequately anticoagulated) has been 
reported for the Medtronic Wiktor stent 
(Bertrand et al. 1990) and for the Wall- 
stent (Serruys et al. 1991). The incidence 
is likely to be particularly high in pa- 
tients with unstable angina and intra- 
coronary thrombus (Bertrand et al. 1990; 
Serruys et al. 1991). It is imperative, 
therefore, that patients in whom stents 
have been implanted be fully anticoagu- 
lated for at least 4-6 weeks, a period that 
corresponds to the time required for 
complete endothelialization of the metal 
struts. Unfortunately, the need for such 
an intensive anticoagulation regimen in- 
l Polymer Stents 
The limitations of metallic intravascular 
stents described above and concerns 
about the unknown long-term effects of 
permanent intravascular devices have 
led to the search for biodegradable ma- 
terials with the structural characteristics 
of metallic stents, but without the poten- 
tial for adverse long-term sequelae. A 
variety of synthetic polymers and deliv- 
ery systems have been evaluated. One 
system uses a temperature-sensitive, 
fenestrated, biodegradable polymer that 
is deployed on a balloon catheter (Sle- 
pian 1990). The polymer is initially 
heated to 60°C with normal saline, which 
allows it to be molded to the desired size 
and shape by balloon inflation within the 
treated vessel. Subsequent cooling 
causes the polymer to assume its original 
solid phase, which has sufficient 
strength to oppose the recoil of the 
dilated vessel. The composition of the 
polymer can be altered to vary the rate of 
its degradation from several weeks to 
many months. In addition to avoiding 
the possible complications of permanent 
metallic devices, this approach has the 
potential advantages of minimizing blood 
flow turbulence and of providing a bar- 
rier to circulating mitogenic and throm- 
bogenic factors. Whether it will in fact 
reduce the incidence of restenosis, how- 
ever, remains to be determined. Few 
data have yet been reported for other 
polymeric stent designs. Two self- 
expanding devices have been evaluated 
experimentally and reported in small 
series. The implantation of a bio- 
degradable L-polylactide stent in canine 
femoral arteries was associated with 
satisfactory early patency in one study 
(Chapman et al. 1990). A second poly- 
meric stent, made from polyethylene 
tetraphthalate, was initially reported to 
be easily implanted and biocompatible 
(Murphy et al. 1990>, but, in longer-term 
follow-up studies, the stent was shown to 
induce a severe local inflammatory reac- 
tion, extensive neointimal proliferation, 
and coronary occlusion (J.G. Murphy, 
personal communication, 1991). 
In addition to the potential for poly- 
mers to intensify the proliferative re- 
sponse, several other factors limit the 
development of polymeric stents. These 
include the need for a reliable delivery 
system, the need for adequate radial 
strength to withstand elastic recoil and 
vasoconstriction without increasing the 
bulk of the stent, and the decay charac- 
teristics (that is, surface versus bulk 
erosion) of biodegradable polymers. The 
only degradable polymers in common 
use display bulk erosion that results in 
degradation of the matrix interior and 
the potential for microembolism and, if 
drug impregnated, for dose dumping. In 
contrast, surface-eroding systems de- 
grade in a more predictable and more 
readily controiled manner (Langer 1990). 
l Prospects for Endovascular 
Pharmacologic Therapy 
Ideally, the advantages of mechanical 
scaffolding of coronary arteries by me- 
tallic or polymeric stents should be 
combined with local pharmacologic ther- 
apy to avoid the need for systemic 
anticoagulation and to inhibit the inti- 
ma1 proliferative response. Although still 
in their infancy, several such approaches 
have been evaluated, including the bond- 
ing of antithrombotic or fibrinolytic 
agents to metallic stents or synthetic 
grafts, the local delivery of drug- 
containing microspheres, the coating of 
stents with genetically modified endo- 
thelial cells, and the use of drug-eluting 
polymeric matrices. 
Heparin Bonding 
Heparin bonding has been used to re- 
duce the thrombogenicity of several in- 
dwelling intravascular devices including 
pulmonary artery catheters (Hoar et al. 
1981; Mangano 1982) and the extracor- 
poreal circuits used for cardiopulmon- 
ary bypass (Lindsay et al. 1976). Prelimi- 
nary experience with heparin-bonded 
tantalum stems implanted in porcine 
carotid arteries has been reported (Cav- 
ender et al. 1990). These investigators 
noted no difference in the incidence of 
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thrombosis and intimal proliferation be- 
tween heparin-bonded and nonhepar- 
inized stents, but very little thrombotic 
or proliferative response was apparent in 
either group. Attempts to bond other, 
more potent, antithrombin agents such 
as hirudin or its synthetic derivative, 
hirulog, that are currently under way 
may reduce the thrombogenicity of me- 
tallic stents and, perhaps, reduce the 
incidence of restenosis following stent 
implantation. Tissue plasminogen acti- 
vator (tPA) has also been noncovalently 
bound to synthetic vascular grafts and 
shown to retain fibrinolytic activity (Har- 
vey et al. 1989). In the presence of 
plasma, however, the fibrinolytic activity 
of the bound tPA was decreased, pre- 
sumably due to the action of circulating 
plasminogen-activator inhibitors. 
Local Drug-Containing Microspheres 
A second means of delivering local an- 
tithrombotic or antiproliferative agents 
to the site of arterial injury is by thermal 
energy-mediated adherence of albumin 
microspheres to the vascular wall. 
McMath et al. (1990) used laser thermal 
energy to apply heparin-entrapped fluo- 
rescent albumin microspheres to the 
endothelium after balloon angioplasty. 
Adherence of the fluorescent micro- 
spheres was apparent for up to 24 h after 
the procedure. A potential limitation of 
this approach is the effect of the laser 
energy itself on smooth muscle cell 
proliferation. Preliminary follow-up data 
from the use of laser balloon angioplasty 
for abrupt coronary closure suggest that 
the restenosis rate may, in fact, be 
considerably higher than in patients 
treated by conventional balloon an- 
gioplasty (Mast et al. 1990). 
Endothelialized Stents 
A more physiologic approach to the 
inhibition of thrombosis and neointimal 
thickening may be to promote early 
endothelialization of the metallic stent 
struts. Under normal circumstances, the 
vascular endothelium plays a critical 
role in the maintenance of vessel patency 
by influencing vascular tone, inhibiting 
or promoting platelet adhesion and throm- 
bosis; it may also inhibit proliferation of 
medial smooth muscle cells through the 
release of heparinlike glycosaminogly- 
cans (Castellot et al. 1987). The feasibil- 
ity of in vitro endothelialization of me- 
tallic stents has been reported (Van der 
Giessen et al. 1988; Dichek et al. 1989). 
In the study by Dichek et al., subsequent 
balloon dilatation was associated with 
loss of endothelial cells on the luminal 
surface of the stent, but satisfactory 
preservation of cells on the exterior and 
lateral surfaces. The effects of this pro- 
cess on in situ thrombus formation have 
not yet been examined. Endothelial seed- 
ing of other vascular prostheses has had 
variable effects on the incidence of sub- 
sequent thrombus formation in man 
(Faso1 et al. 1989; Ortenwall et al. 1990). 
Whether this approach will also reduce 
the severity of neointimal hyperplasia, as 
suggested by one study in which endar- 
terectomized canine carotid arteries were 
seeded with endothelial cells (Bush et al. 
1987), also remains to be determined. 
In addition to simply covering the 
metal surface, endothelial seeding may 
provide other means of reducing the 
thrombogenicity of stents and the inti- 
ma1 thickening that follows their im- 
plantation. Several authors have de- 
scribed the modification of endothelial 
cell function by gene transfer. In the 
study by Dichek ct al. (1989), genes 
encoding the synthesis of tPA and 8- 
galactosidase were inserted into endo- 
thelial cells by retrovirus-mediated trans- 
fer prior to seeding onto the metallic 
stent surface. Secretion of tPA and syn- 
thesis of P-galactosidase by the 
transduced and seeded endothelial cells 
was subsequently confirmed. Direct in 
vivo transfection of endothelial cells has 
also been reported (Nabel et al. 1990) 
and genetically modified endothelial cells 
have been used to cover prosthetic vascu- 
lar grafts (Wilson et al. 1989). This 
approach may allow the delivery at the 
site of stent implantation of the genetic 
material coding not only for the expres- 
sion of plasminogen activators, but also 
for endothelial cell growth factors, angi- 
ogenic factors, or inhibitors of smooth 
muscle cell proliferation. Several factors 
may, however, limit the application of 
this exciting technology to the manage- 
ment of patients in the cardiac catheteri- 
zation laboratory. Issues that must be 
addressed include the need for harvest- 
ing autologous endothelial cells well in 
advance of planned interventional proce- 
dures, the safety of using even replication- 
defective retroviruses for gene transfer, 
the relative merits of ex vivo seeding of 
metallic stents compared with in vivo 
direct gene transfer to adjacent endothe- 
lial cells, means by which direct gene 
transfer can be accomplished without 
prolonged coronary occlusion and myo- 
cardial ischemia, and the duration of 
expression of recombinant genes in vivo. 
Drug-Eluting Polymers 
The approach with perhaps the greatest 
potential (in the near future) for pro- 
longed local pharmacologic therapy is 
the use of controlled-release polymeric 
matrices. These may be used to coat 
metallic stents or, ideally, as endovascu- 
lar stents themselves. Both degradable 
(for example, polyurethane, silicone rub- 
ber, and ethylene vinyl acetate) and 
nondegradable polymers (for instance, 
polyanhydrides and polyglycolic-polylac- 
tic acid) have been used experimentally 
to administer local antiinflammatory, 
antiarrhythmic, and antibiotic agents 
for a variety of cardiovascular indica- 
tions, including the inhibition of bio- 
prosthetic cardiac valve calcification, 
inhibition of ventricular arrhythmias, 
and the prevention of heart-transplant 
rejection (Levy et al. 1990). Heparin- 
eluting ethylene vinyl acetate copoly- 
mers, placed around the adventitial sur- 
face of balloon-injured rat carotid arter- 
ies, were also shown in one study to 
inhibit smooth muscle cell proliferation 
and neointimal thickening (Edelman et 
al. 1990). The development of endovascu- 
lar, drug-eluting polymers has, however, 
been limited by several technical consid- 
erations. In addition to the limitations 
outlined above for polymer stents, incor- 
poration of drugs into sustained-release 
polymer coatings for metallic stents re- 
quires attention to the effects of prepara- 
tion of the polymer on the activity of the 
incorporated agent, the adequacy of drug 
concentrations at the vessel surface be- 
tween the metal struts, the duration of 
drug delivery from the small-volume 
polymer coating, and the elastic charac- 
teristics of the polymer during balloon 
dilatation. 
0 Conclusions 
The use of intravascular, metallic stents 
appears to improve initial angiographic 
appearances and dimensions following 
coronary artery dilatation and provides a 
reliable treatment for the acute man- 
agement of medial dissection and abrupt 
closure. Preliminary data suggest that, 
in certain subgroups, stenting may also 
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reduce the incidence of recurrent sten- 
osis. The widespread application of endo- 
vascular stenting in these patients has 
been limited, however, by the need for 
intensive anticoagulation. Stenting may 
become a first-line treatment for ob- 
structive coronary arterial disease in 
selected patients if the thrombogenic 
potential of the devices can be substan- 
tially reduced by local antithrombotic or 
fibrinolytic therapy. In other patients, 
the use of local pharmacologic or gene- 
transfer therapies, alone or in combina- 
tion with implantable endovascular de- 
vices, may eventually be a valuable means 
of inhibiting the fibroproliferative re- 
sponse that appears to follow all forms of 
arterial injury. 
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